Fund Manager Summary on Integral Diagnostics Ltd (ASX:IDX)
Integral Diagnostics Ltd (ASX: IDX) has faced significant challenges recently, including heightened labour costs and weaker-than-expected earnings, leading to a share price decline of approximately 31.7%. Despite these issues, fund managers express bullish long-term views supported by market growth from an aging population, technological advancements such as AI, and upcoming initiatives like the National Lung Cancer Screening Program and MRI deregulation. The completion of the Capital Health acquisition is expected to yield operational synergies, enhancing margins and scale in the metropolitan market. However, concerns persist regarding ongoing staff shortages and cost inflation, which could impact performance. Recent updates indicate a positive Q1 FY2026, with management projecting continued revenue growth and improved margins, signaling a potential reversal in sentiment and offering a more favorable valuation for investors.
Commentary From The Managers
There are 11 insights from 10 fund managers regarding their investment in Integral Diagnostics Ltd (ASX:IDX) available on Thesis Tracker.
Unlock Updates With ThesisTracker Pro
Don’t let information asymmetry undermine your investment returns. Join other engaged investors on ThesisTracker Pro.
Updates are made available to members within 12 hours of being released. The completeness, accuracy or current status of the investments referenced are not guaranteed.
Commentary From The Managers
LSN Capital Partners
12 Feb 2026
$2.47
Summary
- LSN Capital Partners believes Integral Diagnostics is a dominant, structurally growing diagnostic imaging business trading at a significant discount to M&A peers and continues to hold, with multiple industry tailwinds supporting sustained earnings growth.
- Key structural tailwinds include MRI deregulation, GP bulk billing expansion, and the launch of a lung cancer screening program, all of which are expected to support volume and revenue growth in FY26 and beyond.
- Post-merger synergies have been upgraded to $14 million (from $10 million at the time of the December merger announcement), highlighting management's confidence in integration execution.
- Integral Diagnostics is the #3 player with approximately 14% market share in a structurally growing diagnostic imaging industry, with corporate appeal given ongoing sector consolidation.
- Earnings are forecast to grow at more than 20% per annum over the next three years, underpinned by organic growth tailwinds and merger synergy realisation.
- The stock currently trades at a trailing EBITDA multiple of 7.5x, a significant discount to M&A precedent transactions — Lumus at 17.0x and i-Med at 17.0x — highlighting the valuation upside if the discount narrows.
Wilson Asset Management
10 Nov 2025
$2.56
Summary
- Integral Diagnostics (IDX) delivered a positive Q1 FY2026 update at its AGM.
- Australian revenue increased by 8.3% year-on-year.
- Guidance for FY2026 EBITDA margin is approximately 21%.
- Growth is expected to accelerate in FY2026, supported by MRI deregulation, the National Lung Cancer Screening Program, and the GP Bulk Billing Incentive (effective 1 November).
- Early full-year guidance indicates greater confidence from the board and management regarding revenue, margins, and merger synergies.
- Recent share price decline ahead of the AGM was driven by fears of a weaker trading update, which now appear overdone.
Maple-Brown Abbott
10 Oct 2025
$2.71
Summary
- Maple-Brown Abbott notes that Integral Diagnostics Ltd has experienced a chequered history, with the share price halving over recent years.
- Previous management missteps have impacted performance, but the current positioning shows promise.
- Industry data for radiology is rebounding strongly, indicating a recovery from the long COVID hangover.
- Regulatory tailwinds, such as the deregulation of MRI licenses and national lung cancer screening, are expected to boost volume in the coming years.
- Cost synergies from the Capital Health acquisition may be greater than anticipated.
- Valuation appears attractive, as recent private equity deals in the sector have been priced significantly higher than Integral's current trading levels.
- Maple-Brown Abbott believes earnings have reached an inflection point, suggesting potential for growth.
Seneca Financial Solutions
10 Oct 2025
$2.71
Summary
- Seneca Financial Solutions continues to evaluate the performance of Integral Diagnostics Ltd amidst an ageing population and healthcare trends.
- The diagnostic imaging sector has shown mediocre returns, with only 5% growth and 5% return on equity.
- Concerns about labour force inflation and challenges from boutique practices impact the company's potential.
- Regulatory tailwinds may exist, but forecasting these changes is not a primary focus for Seneca Financial Solutions.
- While there is interest in IDX, it does not align with Seneca's investment strategy at this time.
Yarra Capital Management
28 Feb 2025
$2.13
Summary
- Integral Diagnostics (IDX) remains in a modest overweight position.
- Recent performance was affected by a weaker-than-expected first-half result.
- Results showed higher costs and lower margins.
- Yarra Capital Management believes in the strong long-term fundamentals of radiology.
- Market growth potential is supported by an aging population and new tests.
- Productivity opportunities are expected from technological advancements such as AI.
Blackwattle Investment Partners
28 Feb 2025
$2.13
Summary
- Integral Diagnostics fell 31.7%, making it the key detractor for the month.
- The company reported higher-than-expected labour costs in its radiology centres due to an industry-wide shortage of medical staff.
- The unexpected costs led to a 5% downgrade to consensus earnings forecasts.
- Despite this, the sharp share price drop suggests investors were expecting an upgrade, given strong sector tailwinds.
- Key drivers for long-term structural growth include preventative screening, telehealth, and AI-driven cost efficiencies.
- In a post-results meeting, the CEO and CFO reaffirmed their commitment to unlocking scale efficiency benefits from the Capital Health acquisition.
- If successfully executed, this presents significant upside potential for the company.
- Blackwattle Investment Partners continues to hold because they see the share price movement as a timing issue and believe the investment thesis remains intact.
Tyndall Asset Management
28 Feb 2025
$2.13
Summary
- Tyndall Asset Management exited their investment in Integral Diagnostics prior to the 1H25 results.
- The decision was influenced by anticipated downgrades that were expected to impact share prices.
- Concerns about cost issues were significant leading up to the results.
- These concerns were validated by the results, which contributed to an earnings downgrade.
- The exit was a proactive measure in response to the potential for a heavy share price decline.
Wilson Asset Management
28 Feb 2025
$2.13
Summary
- Integral Diagnostics provides diagnostic services to patients.
- FY2025 interim results fell short of market expectations, impacting share price.
- Reported a statutory loss after tax of $0.4 million.
- Loss attributed to clinical staff shortages and high labour cost inflation in regional Australia.
- Despite challenges, there was solid revenue growth.
- Merger with Capitol Health expected to enhance scale and improve margins.
- Wilson Asset Management continues to hold due to potential growth in metropolitan areas.
Firetrail Investments
30 Nov 2024
$2.85
Summary
- Firetrail Investments continues to hold its position in Integral Diagnostics (IDX).
- IDX experienced Q1 revenue growth of 8% in Australia, below the industry growth rate of 11%.
- The company’s performance is impacted by its greater regional mix and capped contracts that reset at the beginning of Q2.
- Over a 2-year period, IDX has matched industry growth at 8% p.a..
- Industry growth is primarily driven by a shift to higher modality, more expensive scans, Medicare indexation, and volume growth.
Elston Asset Management
30 June 2024
$2.59
Summary
- Integral Diagnostics announced intentions to acquire Capitol Health, a domestic diagnostic imaging peer.
- Elston is cautious of large acquisitions, as they often overpromise and underdeliver for shareholders.
- The businesses are geographically complementary, with Capitol Health sites concentrated in the Melbourne metro area blending well with Integral Diagnostics’ regional sites.
- There are still several hurdles to meet before the acquisition becomes a done deal.
- Elston will closely monitor the progress and seek further details as the acquisition looks more likely to materialise.
Forager Funds
30 June 2024
$2.59
Summary
- Forager Funds has adjusted its position in Integral Diagnostics (IDX), contributing a 2.2% decrease in the Fund’s return.
- Revenue growth remained robust in Australia, indicating positive market performance.
- New Zealand's revenue growth was noted to be weaker.
- Rising clinical staff shortages have led to increased costs and impacted margins early in the financial year.
- High levels of debt have raised concerns regarding financial stability.
- Reduced confidence in long-term margins prompted Forager Funds to reduce their investment.
The completeness, accuracy or current status of the investments referenced are not guaranteed.
Frequently Asked Questions
Who is investing in Integral Diagnostics Ltd (ASX:IDX)?
Fund managers including Blackwattle Investment Partners, Forager Funds, Yarra Capital Management, Elston Asset Management, Firetrail Investments, Wilson Asset Management, Tyndall Asset Management, Seneca Financial Solutions, Maple-Brown Abbott and LSN Capital Partners have invested in Integral Diagnostics Ltd (ASX:IDX).
Why do fund managers invest in Integral Diagnostics Ltd?
Fund managers invest in Integral Diagnostics Ltd primarily due to its strong long-term growth prospects in the radiology sector. Despite recent challenges such as higher labor costs and lower margins affecting short-term results, the company stands to benefit from industry tailwinds like an aging population and advancements in technology, including AI. The recent Capital Health acquisition is anticipated to unlock operational synergies, improving margins and driving scale. Overall, the risk/reward profile is supported by solid revenue growth and attractive valuation metrics.
What happened to Integral Diagnostics Ltd (ASX:IDX)?
Fund managers are considering investing in Integral Diagnostics Ltd due to its potential for growth driven by industry recovery and regulatory changes. Recent comments highlight positive Q1 results with 8.3% year-on-year revenue growth and a projected EBITDA margin of around 21% for FY2026. Factors such as MRI licence deregulation, the National Lung Cancer Screening Program, and cost synergies from recent acquisitions are seen as catalysts for improved performance. Although some caution remains regarding past management issues and sector averages, the current valuation is perceived as attractive, indicating a possibility for future earnings growth.
What is the short interest in Integral Diagnostics Ltd (ASX:IDX)?
The short interest in Integral Diagnostics Ltd (ASX:IDX) is 2.31% which makes it the 114th most shorted stock on the ASX. Of the 372.9M shares that Integral Diagnostics Ltd has on issue, 8.6M have been sold short.
What does Integral Diagnostics Ltd (ASX:IDX) do?
Integral Diagnostics Ltd. engages in the provision of diagnostic imaging services to general practitioners, medical specialists, and allied professionals. It operates under three core brands: Lake Imaging, South Coast Radiology, and Global Diagnostics. The company was founded in 1967 and is headquartered in North Melbourne, Australia.